Genetic predisposition to bleeding during oral anticoagulants treatment
Palabras clave : 
Oral anticoagulants
Vitamin K.
Hemorrhage
Cytochrome P450 2C9
VKORC1
Fecha incorporación: 
2008
Editorial : 
Gobierno de Navarra. Departamento de Salud
ISSN: 
1137-6627
Cita: 
Montes Diaz R, Nantes O, Molina E, Zozaya J, Hermida J. Genetic predisposition to bleeding during oral anticoagulants treatment. An Sist Sanit Navar 2008 Sep-Dec;31(3):247-257.
Resumen
The degree of anticoagulation obtained during oral anticoagulation therapy with vitamin K antagonists (VKA) varies among patients due to individual and environmental factors. The rate of anticoagulation influences the hemorrhagic risk. Therefore, it is plausible that patients specially sensitive to oral anticoagulants are at higher hemorrhagic risk, specially during the first weeks. The role of a series of polymorphisms of the enzymes involved in the metabolism of VKA or in the vitamin K cycle are reviewed. Three polymorphisms, two in the cytochrome P450 2C9 and one in the VKORC1 enzyme, are responsible for a high portion of the variability observed in the sensitivity to AVK. Although the available literature suggests that these genetic variants could increase the risk of severe hemorrhage, larger, well designed studies are needed to confirm this notion.

Ficheros en este registro:
No hay ficheros asociados a este ítem.


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.